The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
A single-center,prospective interventional study to explore the efficacy of PD-1 antibody
Sintilimab on early-stage multiple primary lung cancer patients with ground-glass nodules in
CT scan.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University